BiotechTube

Simvastatin + Simvastatin/Ezetimibe

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Metabolic Syndrome

Conditions

Metabolic Syndrome

Trial Timeline

Apr 1, 2009 → Sep 1, 2010

NCT ID
NCT00817843

About Simvastatin + Simvastatin/Ezetimibe

Simvastatin + Simvastatin/Ezetimibe is a approved stage product being developed by Merck for Metabolic Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00817843. Target conditions include Metabolic Syndrome.

What happened to similar drugs?

14 of 20 similar drugs in Metabolic Syndrome were approved

Approved (14) Terminated (3) Active (6)
✅Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mgYuhanApproved
🔄Olmesartan medoxomil tablets low dose + Olmesartan medoxomil tablets high dose + AmlodipineDaiichi SankyoPhase 3
🔄olmesartan medoxomil + placebo + olmesartan medoxomil + olmesartan medoxomilDaiichi SankyoPhase 3
🔄Tirzepatide + Retatrutide + PlaceboEli LillyPhase 3
✅Metformin + PlaceboEli LillyApproved
✅Henagliflozin 10 mg daily + Metformin 1700 mg dailyJiangsu Hengrui MedicineApproved
🔄RosuvastatinAstraZenecaPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00817843ApprovedCompleted

Competing Products

20 competing products in Metabolic Syndrome

See all competitors
ProductCompanyStageHype Score
Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mgYuhanApproved
35
Olmesartan medoxomil tablets low dose + Olmesartan medoxomil tablets high dose + AmlodipineDaiichi SankyoPhase 3
40
olmesartan medoxomil + placebo + olmesartan medoxomil + olmesartan medoxomilDaiichi SankyoPhase 3
40
14C-labeled YM178Astellas PharmaPhase 1
29
TRC150094Torrent PharmaceuticalsPhase 1/2
32
LY518674Eli LillyPhase 2
35
Tirzepatide + Retatrutide + PlaceboEli LillyPhase 3
47
Metformin + PlaceboEli LillyApproved
43
Tirzepatide + SemaglutideEli LillyPre-clinical
18
LY3849891 + PlaceboEli LillyPhase 1
33
Henagliflozin 10 mg daily + Metformin 1700 mg dailyJiangsu Hengrui MedicineApproved
50
RosuvastatinAstraZenecaPhase 3
40
Rosuvastatin + AtorvastatinAstraZenecaApproved
43
AZD2693 + PlaceboAstraZenecaPhase 1
29
RosuvastatinAstraZenecaPhase 3
40
Rosuvastatin + AtorvastatinAstraZenecaPhase 3
40
rosuvastatinAstraZenecaApproved
43
EfinopegdutideMerckPhase 2
35
MK0767 + Comparator: fenofibrate + Comparator: Placebo (unspecified)MerckPhase 2
27
Vericiguat + PlaceboMerckPhase 2
35